Written questions by Andrew.

Whether his Department monitors the number of newly qualified nurses who are unable to secure NHS nursing posts within six months of qualification.

Awaiting answer.

What assessment his Department has made of the availability of Band 5 nursing posts for newly qualified nurses in Greater Manchester.

Awaiting answer.

What steps his Department is taking to align the number of nursing training places with the number of NHS posts available to newly qualified nurses.

Awaiting answer.

What assessment his Department has made of the adequacy of the number of Band 5 nursing posts available to newly qualified nurses in England.

Awaiting answer.

Whether his Department has made an assessment of the impact of NHS provider financial controls on the recruitment of newly qualified nurses into Band 5 nursing posts.

Awaiting answer.

Whether NHS England routinely monitors geographical variation in the delivery of specialised services including left atrial appendage occlusion or closure; and what action it takes where provision is concentrated in a small number of provider centres.

Awaiting answer.

What steps he is taking to ensure that adults who are already older than the eligible age when the shingles vaccination programme is expanded are not disadvantaged by the timing of the rollout.

Awaiting answer.

What assessment NHS England has made of the impact of centralisation of left atrial appendage occlusion or closure services on patient travel times and waiting times.

Awaiting answer.

What estimate his Department has made of the cost to the NHS of shingles-related GP appointments, A&E attendances and hospital admissions among adults aged 80 and over between the Joint Committee on Vaccination and Immunisation’s November 2024 advice on expanding eligibility and the date on which that advice is implemented.

Awaiting answer.

What factors his Department is considering before responding to the Joint Committee on Vaccination and Immunisation’s November 2024 advice that the shingles vaccination programme should be expanded to include adults aged 80 and over.

Awaiting answer.

Whether the Advisory Council on the Misuse of Drugs’ review of cannabis-based products for medicinal use will specifically consider prescribing to patients with serious mental illness, advertising by private clinics, prescribing volume oversight and cross-regulatory accountability.

Awaiting answer.

What assessment his Department has made of the adequacy of current arrangements for monitoring prescribing volumes of cannabis-based products for medicinal use by provider and prescriber.

Awaiting answer.

Whether his Department has asked the Advisory Council on the Misuse of Drugs to consider patient safety issues in its review of cannabis-based products for medicinal use, including prescribing to patients with serious mental illness, advertising by private clinics, prescribing volume oversight and cross-regulatory accountability.

Awaiting answer.

What estimate his Department has made of the number of adults aged 80 and over who may develop shingles between the Joint Committee on Vaccination and Immunisation’s November 2024 advice on expanding eligibility and the date on which that advice is implemented.

Awaiting answer.

What assessment his Department has made of the clinical, operational, procurement and supply-side barriers to expanding the shingles vaccination programme to adults aged 80 and over.

Awaiting answer.

What operational, clinical or supply-side factors informed the decision to phase the expansion of the shingles vaccination programme to adults aged 60 and over between 2028 and 2033.

Awaiting answer.

How many provider centres approved to deliver left atrial appendage occlusion or closure services are currently inactive or not routinely delivering procedures; and what steps NHS England is taking to ensure sufficient national and regional capacity.

Awaiting answer.

On what dates the Cannabis Interchange Group has met since 1 January 2020; who attended each meeting; and whether she plans to publish the agendas, minutes and papers of those meetings.

Awaiting answer.

What discussions his Department has had with the MHRA on the regulation of private clinics advertising consultations for cannabis-based products for medicinal use.

Awaiting answer.

Whether NHS England will commission a national assessment of regional variation in access to left atrial appendage occlusion or closure services.

Awaiting answer.